NfL and GFAP as Measures of Disease Progression Prospective study to evaluate Neurofilament Light (NfL) and glial fibrillary acidic protein (GFAP) as biomarkers for disease progression over time in patients…
Read More
Biomarkers are biological markers that can be used in diagnosis, selecting treatments, and evaluating treatment responses. Having pre-collected samples is invaluable for this research, and the Biobank ensures that researchers…
A whole new family of drugs is currently being studied very aggressively for the treatment of MS: Tyrosine kinases Inhibitors. Tyrosine kinases (TYKs) are intracellular enzymes that play a key…
A biomarker is any measurable indicator that can reliably and accurately tell us about a biological state or medical condition. As we continue to learn more about MS and utilize…
With current disease modifying therapies (DMTs) we have several highly effective treatments that work for many people, but there is a percentage of the population for whom these medications do…
Repair of MS damage and the potential for the reversal of the effects of MS are always on the minds of doctors, researchers and those living with the disease. Despite…
Over the past several months, there has been increased interest in the relationship between the Epstein Barr Virus and multiple sclerosis. A study conducted by a Harvard University research team…
Not Exactly… But Vaccines and Boosters Remain Our Best Defense COVID-19 continues to twist and turn as new variants become more predominant. The BQ1 and BQ1.1 variants have become the…
In this issue, we’ve compiled six reports on “hot topics” in the MS world. These topics are based on both input from the Rocky Mountain MS Center medical team, and…
COVID-19 continues to twist and turn as new variants become more predominant. The BQ1 and BQ1.1 variants have become the dominant strains in the US as of mid-November. These variants…
You're Reading:
About the Author
This content was compiled by Rocky Mountain MS Center staff members.